Regen BioPharma, Inc. Logo

Regen BioPharma, Inc.

RGBPP

(1.8)
Stock Price

0,06 USD

-511.07% ROA

16.75% ROE

-1.07x PER

Market Cap.

8.204.804,00 USD

-13.94% DER

0% Yield

-367.59% NPM

Regen BioPharma, Inc. Stock Analysis

Regen BioPharma, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Regen BioPharma, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 PBV

The stock's low PBV ratio (-1.33x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-12%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-63.83%) on shareholders' equity, suggesting poor financial performance.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-2) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Regen BioPharma, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Regen BioPharma, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Regen BioPharma, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Regen BioPharma, Inc. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 0 0%
2015 192.000 100%
2016 100.000 -92%
2017 110.000 9.09%
2018 100.000 -10%
2019 110.000 9.09%
2020 110.000 0%
2021 171.194 35.75%
2022 235.517 27.31%
2023 236.560 0.44%
2024 236.260 -0.13%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Regen BioPharma, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 42.516
2013 8.394 -406.5%
2014 23.867 64.83%
2015 282.295 91.55%
2016 671.095 57.94%
2017 1.149.663 41.63%
2018 374.436 -207.04%
2019 45.605 -721.04%
2020 13.286 -243.26%
2021 36.704 63.8%
2022 275.388 86.67%
2023 212.297 -29.72%
2024 130.000 -63.31%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Regen BioPharma, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 358.740
2013 311.442 -15.19%
2014 682.487 54.37%
2015 1.888.980 63.87%
2016 2.385.867 20.83%
2017 1.471.222 -62.17%
2018 1.151.347 -27.78%
2019 821.180 -40.21%
2020 306.031 -168.33%
2021 335.260 8.72%
2022 299.734 -11.85%
2023 711.212 57.86%
2024 538.124 -32.17%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Regen BioPharma, Inc. EBITDA
Year EBITDA Growth
2012 0
2013 -319.836 100%
2014 -706.121 54.71%
2015 -1.978.128 64.3%
2016 -7.704.173 74.32%
2017 -2.455.155 -213.8%
2018 -1.685.747 -45.64%
2019 -753.752 -123.65%
2020 -209.317 -260.1%
2021 -200.540 -4.38%
2022 -321.950 37.71%
2023 -936.949 65.64%
2024 -431.864 -116.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Regen BioPharma, Inc. Gross Profit
Year Gross Profit Growth
2012 0
2013 0 0%
2014 0 0%
2015 192.000 100%
2016 100.000 -92%
2017 110.000 9.09%
2018 100.000 -10%
2019 110.000 9.09%
2020 110.000 0%
2021 146.194 24.76%
2022 185.517 21.2%
2023 176.560 -5.07%
2024 146.260 -20.72%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Regen BioPharma, Inc. Net Profit
Year Net Profit Growth
2012 -401.256
2013 -355.034 -13.02%
2014 -756.353 53.06%
2015 -11.195.147 93.24%
2016 -7.750.594 -44.44%
2017 -5.839.039 -32.74%
2018 -4.715.200 -23.83%
2019 -4.324.130 -9.04%
2020 1.788.602 341.76%
2021 -7.132.030 125.08%
2022 5.436.455 231.19%
2023 1.023.508 -431.16%
2024 -468.432 318.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Regen BioPharma, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Regen BioPharma, Inc. Free Cashflow
Year Free Cashflow Growth
2012 -401.256
2013 -284.836 -40.87%
2014 -746.891 61.86%
2015 -11.012.283 93.22%
2016 -1.672.245 -558.53%
2017 -1.894.419 11.73%
2018 -1.578.039 -20.05%
2019 -481.793 -227.53%
2020 18.645 2684.03%
2021 -1.130.938 101.65%
2022 -606.921 -86.34%
2023 -173.917 -248.97%
2024 -172.589 -0.77%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Regen BioPharma, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -401.256
2013 -284.836 -40.87%
2014 -746.891 61.86%
2015 -11.012.283 93.22%
2016 -1.672.245 -558.53%
2017 -1.894.419 11.73%
2018 -1.578.039 -20.05%
2019 -481.793 -227.53%
2020 18.645 2684.03%
2021 -1.130.938 101.65%
2022 -606.921 -86.34%
2023 -173.917 -248.97%
2024 -172.589 -0.77%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Regen BioPharma, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Regen BioPharma, Inc. Equity
Year Equity Growth
2012 -167.180
2013 115.922 244.22%
2014 -129.631 189.42%
2015 -97.187 -33.38%
2016 -586.902 83.44%
2017 -5.251.335 88.82%
2018 -9.121.671 42.43%
2019 -10.908.794 16.38%
2020 -7.334.998 -48.72%
2021 -13.485.877 45.61%
2022 -8.036.059 -67.82%
2023 -5.103.999 -57.45%
2024 -5.157.712 1.04%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Regen BioPharma, Inc. Assets
Year Assets Growth
2012 923
2013 115.922 99.2%
2014 10.655 -987.96%
2015 220.452 95.17%
2016 319.356 30.97%
2017 944.239 66.18%
2018 209.018 -351.75%
2019 99.087 -110.94%
2020 123.189 19.57%
2021 1.212.099 89.84%
2022 559.002 -116.83%
2023 353.617 -58.08%
2024 170.150 -107.83%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Regen BioPharma, Inc. Liabilities
Year Liabilities Growth
2012 0
2013 0 0%
2014 140.286 100%
2015 317.639 55.83%
2016 906.258 64.95%
2017 6.195.574 85.37%
2018 9.330.689 33.6%
2019 11.007.881 15.24%
2020 7.458.187 -47.59%
2021 14.697.976 49.26%
2022 8.595.061 -71%
2023 5.457.616 -57.49%
2024 5.327.862 -2.44%

Regen BioPharma, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.06
Net Income per Share
-0.21
Price to Earning Ratio
-1.07x
Price To Sales Ratio
34.68x
POCF Ratio
-1.63
PFCF Ratio
-14.45
Price to Book Ratio
-0.18
EV to Sales
37.46
EV Over EBITDA
-13.83
EV to Operating CashFlow
-15.61
EV to FreeCashFlow
-15.61
Earnings Yield
-0.94
FreeCashFlow Yield
-0.07
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
2.38
Graham NetNet
-1.24

Income Statement Metrics

Net Income per Share
-0.21
Income Quality
0.61
ROE
0.17
Return On Assets
-4.9
Return On Capital Employed
0.08
Net Income per EBT
0.94
EBT Per Ebit
2.37
Ebit per Revenue
-1.65
Effective Tax Rate
0.16

Margins

Sales, General, & Administrative to Revenue
2
Research & Developement to Revenue
0.66
Stock Based Compensation to Revenue
1.06
Gross Profit Margin
0.71
Operating Profit Margin
-1.65
Pretax Profit Margin
-3.92
Net Profit Margin
-3.68

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.13
Free CashFlow per Share
-0.13
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.07
Return on Tangible Assets
-5.11
Days Sales Outstanding
103.6
Days Payables Outstanding
154.01
Days of Inventory on Hand
0
Receivables Turnover
3.52
Payables Turnover
2.37
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-1,22
Tangible Book Value per Share
-1.22
Shareholders Equity per Share
-1.22
Interest Debt per Share
0.19
Debt to Equity
-0.14
Debt to Assets
4.23
Net Debt to EBITDA
-1.03
Current Ratio
0.03
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-5175445
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2600
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Regen BioPharma, Inc. Dividends
Year Dividends Growth

Regen BioPharma, Inc. Profile

About Regen BioPharma, Inc.

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.

CEO
Dr. David Raymond Koos DBA, Ph
Employee
1
Address
4700 Spring Street
La Mesa, 91942

Regen BioPharma, Inc. Executives & BODs

Regen BioPharma, Inc. Executives & BODs
# Name Age
1 Dr. David Raymond Koos DBA, Ph.D.
Chairman, Chief Executive Officer, President, Secretary & Treasurer
70

Regen BioPharma, Inc. Competitors